AN2025 (Buparlisib)
Recurrent or metastatic Head and Neck Squamous Cell Carcinoma
Key Facts
Indication
Recurrent or metastatic Head and Neck Squamous Cell Carcinoma
Phase
Phase 3
Status
Active
Company
About Adlai Nortye
Adlai Nortye is a clinical-stage biotech focused on developing innovative oncology therapies, with a core strategy of in-licensing and advancing mid-to-late-stage assets into new, high-need indications. Its most advanced candidate, buparlisib (AN2025), is in a pivotal global Phase 3 trial for head and neck squamous cell carcinoma (HNSCC). The company aims to address significant unmet medical needs by modulating the tumor microenvironment and overcoming resistance to standard treatments like anti-PD-1 therapy.
View full company profile